Literature DB >> 20042714

The loss of tuberin promotes cell invasion through the ß-catenin pathway.

Elizabeth A Barnes1, Heidi L Kenerson, Baldwin C Mak, Raymond S Yeung.   

Abstract

Mutations in the tumor suppressor tuberin (TSC2) are a common factor in the development of lymphangioleiomyomatosis (LAM). LAM is a cystic lung disease that is characterized by the infiltration of smooth muscle-like cells into the pulmonary parenchyma. The mechanism by which the loss of tuberin promotes the development of LAM has yet to be elucidated, although several lines of evidence suggest it is due to the metastasis of tuberin-deficient cells. Here we show that tuberin-null cells become nonadherent and invasive. These nonadherent cells express cleaved forms of β-catenin. In reporter assays, the β-catenin products are transcriptionally active and promote MMP7 expression. Invasion by the tuberin-null cells is mediated by MMP7. Examination of LAM tissues shows the expression of cleaved β-catenin products and MMP7 consistent with a model that tuberin-deficient cells acquire invasive properties through a β-catenin-dependent mechanism, which may underlie the development of LAM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042714      PMCID: PMC2970858          DOI: 10.1165/rcmb.2008-0335OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  44 in total

1.  Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis.

Authors:  K Matsui; K Takeda; Z X Yu; W D Travis; J Moss; V J Ferrans
Journal:  Arch Pathol Lab Med       Date:  2000-02       Impact factor: 5.534

2.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Authors:  Elena A Goncharova; Dmitriy A Goncharov; Poay N Lim; Daniel Noonan; Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2005-12-30       Impact factor: 6.914

Review 3.  Matrix metalloproteinases in development and disease.

Authors:  Vincent Lemaître; Jeanine D'Armiento
Journal:  Birth Defects Res C Embryo Today       Date:  2006-03

Review 4.  Wnt/beta-catenin signaling in development and disease.

Authors:  Hans Clevers
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

5.  Analysis of cell proliferation and cell survival by continuous BrdU labeling and multivariate flow cytometry.

Authors:  M Poot; M Rosato; P S Rabinovitch
Journal:  Curr Protoc Cytom       Date:  2001-05

6.  Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification.

Authors:  Yoshihiro Tamamura; Tomohiro Otani; Naoko Kanatani; Eiki Koyama; Jirota Kitagaki; Toshihisa Komori; Yoshihiko Yamada; Frank Costantini; Satoshi Wakisaka; Maurizio Pacifici; Masahiro Iwamoto; Motomi Enomoto-Iwamoto
Journal:  J Biol Chem       Date:  2005-03-10       Impact factor: 5.157

7.  Aberrant beta-catenin signaling in tuberous sclerosis.

Authors:  Baldwin C Mak; Heidi L Kenerson; Lauri D Aicher; Elizabeth A Barnes; Raymond S Yeung
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

8.  Tissue inhibitor of metalloproteinase-1 moderates airway re-epithelialization by regulating matrilysin activity.

Authors:  Peter Chen; John K McGuire; Robert C Hackman; Kyoung-Hee Kim; Roy A Black; Kurt Poindexter; Wei Yan; Phillip Liu; Ann J Chen; William C Parks; David K Madtes
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

9.  Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.

Authors:  Umut Ozcan; Lale Ozcan; Erkan Yilmaz; Katrin Düvel; Mustafa Sahin; Brendan D Manning; Gökhan S Hotamisligil
Journal:  Mol Cell       Date:  2008-03-14       Impact factor: 17.970

10.  Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms.

Authors:  Heidi Kenerson; Andrew L Folpe; Thomas K Takayama; Raymond S Yeung
Journal:  Hum Pathol       Date:  2007-05-22       Impact factor: 3.466

View more
  12 in total

Review 1.  Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.

Authors:  Vera P Krymskaya; Francis X McCormack
Journal:  Annu Rev Med       Date:  2017-01-14       Impact factor: 13.739

2.  Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition.

Authors:  Elizabeth A Barnes; Heidi L Kenerson; Xiuyun Jiang; Raymond S Yeung
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

3.  CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Mary E Haughey; Patricia A Julien-Williams; Mario P Stylianou; Bernadette R Gochuico; Joel Moss
Journal:  Chest       Date:  2017-05-30       Impact factor: 9.410

Review 4.  Lymphangioleiomyomatosis - a wolf in sheep's clothing.

Authors:  Elizabeth P Henske; Francis X McCormack
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

5.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

6.  Pygopus 2 promotes kidney cancer OS-RC-2 cells proliferation and invasion in vitro and in vivo.

Authors:  Rongfu Liu; Xiangcheng Qin; Chengyong Ji; Weixin Zeng; Yufeng Yang; Wei Tan
Journal:  Asian J Urol       Date:  2015-07-18

7.  Microbial Antigens Stimulate Metalloprotease-7 Secretion in Human B-Lymphocytes Using mTOR-Dependent and Independent Pathways.

Authors:  Mohamed F Ali; Harika Dasari; Virginia P Van Keulen; Divi Cornec; George Vasmatzis; Tobias Peikert; Eva M Carmona
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

8.  Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment.

Authors:  Yi Liu; Zhibin Guo; Chenlong Zhao; Xin Li; Hongyu Liu; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-08-31       Impact factor: 4.147

9.  mTOR and S6K1 drive polycystic kidney by the control of Afadin-dependent oriented cell division.

Authors:  Martina Bonucci; Nicolas Kuperwasser; Serena Barbe; Vonda Koka; Delphine de Villeneuve; Chi Zhang; Nishit Srivastava; Xiaoying Jia; Matthew P Stokes; Frank Bienaimé; Virginie Verkarre; Jean Baptiste Lopez; Fanny Jaulin; Marco Pontoglio; Fabiola Terzi; Benedicte Delaval; Matthieu Piel; Mario Pende
Journal:  Nat Commun       Date:  2020-06-24       Impact factor: 14.919

10.  Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.

Authors:  Darío García-Carracedo; Maria Ángeles Villaronga; Saúl Álvarez-Teijeiro; Francisco Hermida-Prado; Iñigo Santamaría; Eva Allonca; Laura Suárez-Fernández; Maria Victoria Gonzalez; Milagros Balbín; Aurora Astudillo; Pablo Martínez-Camblor; Gloria H Su; Juan Pablo Rodrigo; Juana María García-Pedrero
Journal:  Oncotarget       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.